Trading The Top Triglyceride Challengers [View article]
I think everyone misses the point of investing in Neptune.....it's going to increase in value based on current market cap and projected sales of NKO. Any value added from its subsidiaries will just be icing on the cake. Pretty low risk value and growth play with surprise upside potential.
Galena's Data Insinuates Big Upside, While Valuation Presents Minimal Downside [View article]
I think this company would be bought out before it got to that valuation. If interim results for phase 3 are consistent with phase 2, a buyout may come quickly. This scenario may play out different if they have a partner; which they are currently seeking. I think obtaining a partner is the best path forward for Galena.
Galena's Data Insinuates Big Upside, While Valuation Presents Minimal Downside [View article]
My understanding is that NeuVax would be prescribed after current standard of care. It would be used to prevent the recurrence of cancer. The high success in preventing recurrence would be revolutionary, but it would not change the initial treatment patients receive. Post standard of care therapy is the market Galena is after, and there is no (or not much) competition in this area. Please let me know if my view is correct.
Thursday's Biotech Opportunity: Antares Pharma [View article]
Trading The Top Triglyceride Challengers [View article]
Galena's Data Insinuates Big Upside, While Valuation Presents Minimal Downside [View article]
Galena's Data Insinuates Big Upside, While Valuation Presents Minimal Downside [View article]
Today's Bio Pharma Watch List [View article]
http://bit.ly/M3gnRJ